CancerVax Selected to Receive Upside Magazine's 2002 Hot 100 Award; Award Recognizes Leadership and Innovation Among Technology Companies.Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BW HealthWire)--May 30, 2002 CancerVax(R) Corporation announced today that it has been selected by Upside Magazine to receive the 2002 UPSIDE Hot 100 award, which recognizes leadership, excellence and innovation within the technology industry. This year, CancerVax represents one of seven biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. recognized from among a number of industries, including wireless, semiconductors, optical networking Communications between computers, telephones and other electronic devices using light. An optical network is far more reliable and has far greater potential transmission capacity than networking in the electrical domain. See optical fiber. , biotech, telecom and Internet. The Hot 100 is in its seventh year of existence, and was the first annual award to provide recognition to privately held technology companies. The award showcases leaders in their respective fields who have excelled in areas of technological achievements, financial backing, management savvy and technical success. The selection committee included Upside Magazine editors, venture capitalists, financial analysts, market researchers and other industry luminaries who evaluated more than 400 nominations. "We evaluated hundreds of great companies that spanned a broad range of technology market segments, and we are pleased to recognize CancerVax as one of this year's winners," said Jerry Borrell, editor-in-chief of Upside Magazine. "Over the seven years of its existence, this award has consistently recognized companies that have become the hallmark of excellence in technology, achieving successful IPOs, or merging with other companies. We expect big things from this year's winners and look forward to following CancerVax's success." "We are pleased to receive this award, as it acknowledges the achievements by the Company and its associates over the past year and a half," said David F. Hale, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CancerVax. "We are very excited to be involved in the development of novel biological products for the treatment of cancer, such as our therapeutic cancer vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. CANVAXIN(TM), which is in clinical development for the treatment of melanoma, a deadly form of skin cancer." About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a privately held biotechnology company focused on the research, development and commercialization of novel therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine , angiogenesis inhibitors and monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). for the treatment and control of cancer. The Company's lead product candidate, CANVAXIN(TM), is a therapeutic cancer vaccine currently being studied for the treatment of advanced-stage melanoma and advanced-stage colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. . CancerVax has additional product candidates in pre-clinical development for the treatment of solid tumor cancers, including several monoclonal antibodies that appear to inhibit angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. , the blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. development that is necessary for tumor growth. CancerVax maintains its corporate and R&D headquarters in Carlsbad, California, and its biologics manufacturing facility in Los Angeles, California. CancerVax(R) and CANVAXIN(TM) are trademarks of CancerVax(R) Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion